Open Access
Numéro
Ann Toxicol Anal
Volume 24, Numéro 1, 2012
Page(s) 39 - 47
DOI https://doi.org/10.1051/ata/2012001
Publié en ligne 30 mai 2012
  1. Alper KR. Ibogaine: a review. Alkaloids Chem Biol. 2001; 56: 1-38. [CrossRef] [PubMed]
  2. Schultes RE, Hofmann A. Les plantes des dieux, les plantes hallucinogènes [Plants of the Gods, hallucinogenic plants]. Paris, France : Lezard, 2000.
  3. Alper KR,Lotsof HS,Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008; 115(1): 9–24. [CrossRef] [PubMed]
  4. Document consulté sur le site : http://www.drogues.gouv.fr/fr/pdf/professionnels/ressources/dossier_halluci.pdf le 19 mai 2011.
  5. Boucher A, Descottes J. Potentiel d’utilisation thérapeutique de l’ibogaïne : revue de la littérature. Lyon : C.E.I.P., 2006.
  6. Kontrimavičiūtė V, Mathieu O, Mathieu-Daudé JC, Vainauskas P, Casper T, Baccino E, Bressolle FM. Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub. J Anal Toxicol. 2006; 30(7): 434–440. [PubMed]
  7. Bogusz MJ,Maier RD,Krüger KD,Kohls U. Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography-atmospheric-pressure chemical-ionization mass spectrometry. J Anal Toxicol. 1998; 22(7): 549–558. [PubMed]
  8. Mash DC,Kovera CA,Buck BE,Norenberg MD,Shapshak P,Hearn WL,Sanchez-Ramos J. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci. 1998; 844: 274–292. [CrossRef] [PubMed]
  9. Maas U,Strubelt S. Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Med hypotheses. 2006; 67(4): 960–964. [CrossRef] [PubMed]
  10. Chèze M,Lenoan A,Deveaux M,Pépin G. Determination of ibogaine and noribogaine in biological fluids and hair by LC-MS/MS after Tabernanthe iboga abuse Iboga alkaloids distribution in a drowning death case. Forensic Sci Int. 2008; 176(1): 58–66. [CrossRef] [PubMed]
  11. Document consulté sur le site : http://www.myeboga.com/fatalities.html le 10 mai 2011.
  12. Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of Ibogaine. J Forensic Sci. 2012; 57(2): 398–412. [CrossRef] [PubMed]
  13. Gallagher CA, Hough LB, Keefner SM, Seyed-Mozaffari A,Archer S,Glick SD. Identification and quantification of the indole alkaloid ibogaine in biological samples by gas chromatography-mass spectrometry. Biochem Pharmacol. 1995; 49(1): 73–79. [CrossRef] [PubMed]
  14. Hearn WL, Pablo J, Hime GW, Mash DC. Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry. J Anal Toxicol. 1995; 19(6): 427–434. [PubMed]
  15. Alburges ME, Foltz RL, Moody DE. Determination of ibogaine and 12-hydroxy-ibogamine in plasma by gas chromatography-positive ion chemical ionization-mass spectrometry. J Anal Toxicol. 1995; 19(6): 381–386. [PubMed]
  16. Ley FR,Jeffcoat AR,THomas BF. Determination of ibogaine in plasma by gas chromatography-chemical ionization mass spectrometry. J Chromatogr A. 1996; 723(1): 101–109. [CrossRef] [PubMed]
  17. Kontrimavičiūtė V,Breton H,Mathieu O,Mathieu-Daudé JC,Bressolle FM. Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to poisoning involving Tabernanthe iboga root. J Chromatogr. 2006; 843(2): 131–141. [CrossRef] [PubMed]
  18. Björnstad K,Beck O,Helander A. A multi-component LC-MS/MS method for detection of ten plant-derived psychoactive substances in urine. J Chromatogr. 2009; 877(11-12): 1162–1168. [CrossRef] [PubMed]
  19. Bévalot F, Gaillard Y, Lemeur C. Utilisation de macro-commandes pour l'optimisation de l'exploitation des chromatogrammes de dépistages systématiques obtenus en GC-MS [The use of macro-commands for the optimization of the use of systematic screening chromatograms obtained through GC/MS]. 11e Congrès de la Société Française de Toxicologie Analytique Dinard, France, 2003.
  20. Gaillard Y, Pepin G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology. J Chromatogr A. 1997; 763(1-2): 149–163. [CrossRef] [PubMed]
  21. Chatenay C, Bévalot F, Gaillard Y. Use of UPLC-PDA/MS in systematic toxicological analysis 47th Congree of The International Association of Forensic Toxicologists Genova, Italy, 2009.
  22. Grusson A, Dingeon B, Dreyfuss M-F, Gaillard Y, Le Bouil A, Lhermitte M, Mazzega S, Moulsma M, Pépin G, Perrin M, Plesse J, Roussel O, Thevenot M-T, Vinner E, Deveaux M. Help for validation of analytical procedures in toxicology and therapeutic drug monitoring. Ann Toxicol Anal. 2005; 17(3): 1–20.
  23. Obach RS,Pablo J,Mash DC. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos. 1998; 26(8): 764–768. [PubMed]
  24. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics. 1998; 8(4): 325–333. [CrossRef]
  25. Hoelen DW, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 2009; 360(3): 308–309. [CrossRef] [PubMed]
  26. 26. Moffat A, Osselton M, Widdop B. Clarke's analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. London, Great Britain: Pharmaceutical Press, 2004.
  27. Krantz MJ,Lewkowiez L,Hays H,Woodroffe MA,Robertson AD,Mehler PS. Torsade de pointes associated with very-high-dose methadone. Annals of Internal Medicine. 2002; 137(6): 501–504. [PubMed]
  28. Krantz MJ,Martin J,Stimmel B,Mehta D,Haigney MC. QTc interval screening in methadone treatment. Annals of Internal Medicine. 2009; 150(6): 387–395. [CrossRef] [PubMed]
  29. Wu D, Otton SV, Sproule BA, Busto U, Inaba T,Kalow W,Sellers EM. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol. 1993; 35(1): 30–34. [PubMed]
  30. Ernst E, Bartu A, Popescu A, Ileutt KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993–1999. Aust N Z J Public Health. 2002; 26(4): 364–370. [CrossRef] [PubMed]
  31. Kuryshev YA, Bruening-Wright A, Brown AM, Kirsch GE. Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels. J Cardiovas Pharmacol. 2010; 56(4): 420–430. [CrossRef]
  32. Pelissier-Alicot A-L, Gaulier J-M, Champsaur P, Marquet P. Mécanismes de la redistribution post-mortem des xénobiotiques : le point sur l'état actuel des connaissances [Mechanisms underlying postmortem redistribution of drugs: about current knowledges]. Ann Toxicol Anal. 2001; 13(1): 1–17. [CrossRef] [EDP Sciences]
  33. Kintz P. Toxicologie et pharmacologie médicolégales [Medicolegal toxicology and pharmacology]. Nancy, France : Elsevier France, 1998.
  34. Vorpahl TE, Coe JI. Correlation of antemortem and postmortem digoxin levels. J Forensic Sci. 1978; 23(2): 329–334. [PubMed]
  35. Hargrove VM,McCutcheon JR. Comparison of drug concentrations taken from clamped and unclamped femoral vessels. J Anal Toxicol. 2008; 32(8): 621–625. [PubMed]